C-MYC and DHFR protein levels at diagnosis were assessed by immunohistochemistry on series of patients treated with either a MTX -based protocol ( IOR/OS-1 ; 72 patients ) or with a standard four-drug regimen ( ISG/ SSG 1 ; 61 patients ) .